Lead Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Age ≥18 years old.
•2. Histopathological diagnosis as FL Grade1, 2 or 3a
•3. The patient is not suitable or refuse the hematopoietic stem cell transplantation(HSCT).
•4. Presence of radiographically measurable lymph nodes or extranodal lesions, defined as at least one lesion longest diameter (LD) measurements \> 1.5 cm and longest vertical diameter (LPD) measurements ≥1.0 cm.
•5. Life expectancy ≥12 weeks.

•1. Known histological transformation of diffuse large B-cell lymphoma (DLBCL) from indolent non-Hodgkin lymphoma (iNHL).
•2. A history of central nervous system lymphoma (primary or metastatic) and leptomeninges dease.
•3. Previously received Idelalisib, other selective PI3Kδ inhibitors or generic PI3K inhibitor treatment.
•4. Previously received Bruton tyrosine kinase inhibitors (e.g., ibrutinib).
•5. pregnant or lactating women.